<DOC>
	<DOCNO>NCT00334867</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vincristine , doxorubicin , cyclophosphamide , ifosfamide , etoposide , topotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Giving chemotherapy surgery may make tumor small reduce amount normal tissue need remove . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know combination chemotherapy regimen effective treat Ewing 's sarcoma . PURPOSE : This randomized phase III trial study combination chemotherapy topotecan see well work compare combination chemotherapy alone treat patient newly diagnose localize Ewing 's sarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Topotecan Treating Patients With Newly Diagnosed Localized Ewing 's Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free overall survival patient newly diagnose localize Ewing 's sarcoma treat doxorubicin hydrochloride , cyclophosphamide , vincristine , etoposide , ifosfamide v without topotecan hydrochloride . - Compare side effect regimens patient . Secondary - Evaluate initial tumor size prognostic factor event-free survival patient . - Evaluate histological response prognostic factor event-free survival patient . - Continue evaluation biologic marker related prognosis eventual therapeutic target via encouraging concurrent enrollment COG-AEWS02B1 . - Evaluate radiologic response positron emission tomography prognostic factor event-free survival . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( ≤ 17 v ≥ 18 year age ) primary tumor site ( pelvic v nonpelvic [ include extra-osseous Ewing 's sarcoma ] ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive vincristine IV 1 minute week day 1 week 1-3 , 7-9 , 13-15 ; doxorubicin hydrochloride IV 15 minute day 1 2 week 1 , 7 , 13 ; cyclophosphamide IV 1 hour day 1 week 1 , 7 , 13 ; ifosfamide IV 1 hour etoposide IV 1 hour day 1-5 week 4 , 10 , 16 . Patients undergo local therapy comprise surgical resection approximately week 18 and/or radiotherapy begin approximately week 19 . Patients receive vincristine week 19-21 , 28-30 , 34-36 , 40-42 , 46-51 ; dexrazoxane hydrochloride IV 15 minute day 1 2 doxorubicin hydrochloride week 19 28 ; cyclophosphamide week 19 , 28 , 34 , 40 , 46 , 49 ; ifosfamide etoposide week 22 , 25 , 31 , 37 , 43 . - Arm II : Patients receive vincristine IV 1 minute week day 1 week 1-3 , 7-9 , 13-16 ; topotecan hydrochloride IV 30 minute day 1-5 week 1 13 ; cyclophosphamide IV 30 minute day 1-5 week 1 13 IV 1 hour day 1 week 7 16 ; ifosfamide IV 1 hour etoposide IV 1 hour day 1-5 week 4 10 ; doxorubicin hydrochloride IV 15 minute day 1 2 week 7 16 . Patients undergo local therapy comprise surgical resection approximately week 18 and/or radiotherapy begin approximately week 19 . Patients receive vincristine week 19-21 , 28-33 , 37-42 , 46-48 ; topotecan hydrochloride week 19 , 31 , 40 ; cyclophosphamide IV 30 minute week 19 , 31 , 40 IV 1 hour week 28 , 37 , 46 ; ifosfamide etoposide week 22 , 25 , 34 , 43 , 49 ; dexrazoxane hydrochloride IV 15 minute day 1 2 week 37 46 ; doxorubicin hydrochloride week 28 , 37 , 46 . After completion study treatment , patient follow periodically 5 year . PROJECTED ACCRUAL : A total 528 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm extracranial Ewing 's sarcoma primitive neuroectodermal tumor ( PNET ) bone soft tissue Chest wall tumor ipsilateral pleural effusion , ipsilateral positive pleural fluid cytology , ipsilateral pleuralbased secondary tumor nodule allow Contralateral pleural effusion pleural nodule eligible Tumor arise bony skull ( extradural ) eligible Tumors arise intradural soft tissue eligible Newly diagnose disease Only biopsy primary tumor without attempt complete partial resection Prior attempt accomplished unplanned excision allow provided adequate imaging obtain prior surgery AND resection consider incomplete local control require No evidence metastatic disease , define lesion discontinuous primary tumor , regional lymph node , share body cavity primary tumor No evidence metastatic lung disease CT scan One pulmonary nodule &gt; 1 cm diameter OR &gt; 1 nodule &gt; 0.5 cm diameter consider evidence pulmonary metastasis Solitary nodules 0.51.0 cm multiple nodule 0.30.5 cm must confirm negative biopsy Solitary nodule &lt; 0.5 cm multiple nodule &lt; 0.3 cm consider clear evidence lung disease No distant nodule disease No esthesioneuroblastoma PATIENT CHARACTERISTICS : Performance status ( PS ) 02 ( Karnofsky PS 50100 % patient ≥ 16 year age Lansky PS 50100 % patient &lt; 16 year age ) Creatinine clearance radioisotope glomerular filtration rate ( GFR ) ≥ 70 mL/min Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT &lt; 2.5 time ULN Shortening fraction ≥ 27 % EKG Ejection fraction ≥ 50 % radionuclide angiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy No prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
</DOC>